A lipid hypothesis: Prediction, observation and the Triglyceride/HDL gap

Current Medical Research and Opinion

Volumn 14, Issue 2, 1998, Pages 65-78

  Deslypere, J P ^a,c   Jackson, G ^b  

^a Vice President and Director   (Indonesia)

^b GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^c NONE   (Belgium)

Author keywords

Cholesterol; Clinical trials; Coronary risk; Fibrates; High density lipoproteins; Low density lipoprotein; Primary prevention; Statins; Triglycerides

Indexed keywords

FIBRIC ACID DERIVATIVE; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; STATINE DERIVATIVE; TRIACYLGLYCEROL;

CHOLESTEROL BLOOD LEVEL; CORONARY RISK; HEART INFARCTION; HEART PROTECTION; HUMAN; HYPERLIPIDEMIA; HYPOTHESIS; LIPID BLOOD LEVEL; PRIMARY PREVENTION; REVIEW; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 0031867160     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/03007999809113345     Document Type: Review

References (30)

1. Shepherd, J., Cobbe, S. M., Ford, I., et al. (1995). Prevention of coronary heart disease with pravastatin in men with hypercholesterolaemia. N. Engl. J. Med., 333, 1301-1307.
2. Scandinavian Simvastatin Survival Study Group (1994). Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study. Lancet, 344, 1383-1389.
3. Wilt, T. J., Davis, B. and Meyers, D. G. (1996). Prevalence and correlates of symptomatic peripheral atherosclerosis in individuals with coronary heart disease and cholesterol levels less than 240mg/dl; baseline results from the cholesterol and recurrent events (CARE) study. Angiology, 47, 533-541.
4. Design rationale and baseline characteristics of the prospective pravastatin pooling (PPP) project - a combined analysis of three large-scale randomised trials: long-term intervention with pravastatin in ischemic disease (LIPID), cholesterol and recurrent events (CARE), and West of Scotland Coronary Prevention Study (WOSCOPS). Am. J. Cardiol., 76, 899-905.
5. The Pravastatin Multinational Study Group for Cardiac Risk Patients (1993). Effects of pravastatin in patients with serum total cholesterol levels from 5.2 to 7.8mmol/l plus two additional atherosclerotic risk factors. Am. J. Cardiol., 72, 1031-1037.
6. Assmann, G., Schulte, H. and von Eckardstein, A. (1996). Hypertriglyceridemia and elevated lipoprotein(a) are risk factors for major coronary events in middle-aged men. Am. J. Cardiol., 77, 1179-1184.
7. Hodis, H. N. and Mack, W. N. (1995). Triglyceride-rich lipoproteins and the progression of coronary artery disease. Curr. Opin. Lipidol., 269, 505-510.
8. Rader, D., Hoeg, J. M. and Brewer, H. B. Jr (1994). Quantitation of plasma apolipoproteins in the primary and secondary prevention of coronary artery disease. Ann. Intern. Med., 120, 1012-1025.
9. Packard, C. (1995). Micro News, Lipid Exchanges. Issue No. 1, Oct. The Lipoprotein Consultancy, Los Altos, USA.
10. Hokanson, J. and Austin, M. A. (1996). Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol: a meta-analysis of population-based prospective studies. J. Cardiovasc. Risk, 3, 213-219.
11. Fuster, V., Badimon, L., Badimon, J. J. et al. (1992). The pathogenesis of coronary artery disease and the acute coronary syndrome. N. Engl. J. Med., 326, 242-309.
12. Brown, B. G., Zhao, W. Q., Sacco, D. E. et al. (1993). Lipid lowering and plaque regression: new insights into prevention of plaque disruption and clinical events in coronary disease. Circulation, 87, 1781-1791.
13. Law, M. R., Wald, N. J. and Wu, T. (1994). Systematic understatement of association between serum cholesterol concentration and ischaemic heart disease in observational studies: data from the BUPA study. BMJ, 308, 363-366.
14. The Lipid Research Clinics Program (1984). The lipid research clinics coronary primary prevention trial results. 1. Reduction in the incidence of coronary heart disease. JAMA, 251, 351-364.
15. Frick, M. H., Elo, O., Haapa, K. et al. (1987). Helsinki Heart Study. Primary-prevention trial with gemfibrozil in middle aged men with dyslipidaemia. Safety of treatment, changes in risk factors and incidence of coronary heart disease. N. Engl. J. Med., 317, 1237-1245.
16. Buchwald, H., Varco, R. L, Matts, J. P. et al. (1990). Effects of partial ileal bypass on mortality and morbidity from coronary heart disease in patients with hypercholesterolaemia. N. Engl. J. Med., 329, 946-955.
17. Carlson, L. A. and Rosenhamer, G. (1988). Reduction of mortality in the Stockholm ischaemic disease secondary prevention study by combined treatment with clofibrate and nicotinic acid. Acta Med. Scand., 223, 405-418.
18. Sacks, F. M., Pfeffer, M. A., Moye, L. A. et al. (1996). The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N. Engl. J. Med., 335, 1001-1009.
19. Ericsson, C.-G., Hamsten, A., Nilsson, J. et al. (1996). Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients. Lancet, 347, 849-853.
20. Bunte, T., Hahmann, H. W., Hellwig, N. et al. (1993). Effects of fenofibrate on angiographically examined coronary atherosclerosis and left ventricular function in hypercholesterolemic patients. Atherosclerosis, 98, 127-138.
21. The MAAS Investigators (1994). Effect of simvastatin on coronary atheroma: the multicentre anti-atheroma study (MAAS). Lancet, 344, 633-638.
22. Jukema, J. E., Bruschke, A. V. G., van Boven, A. J. et al. on behalf of the REGRESS study group (1995). Effect of lipid lowering by pravastatin on progression of coronary artery disease in symptomatic man with normal to moderately elevated serum cholesterol levels: the regression growth evaluation statin study (REGRESS). Circulation, 91, 2528-2540.
23. Caslake, M. J., Packard, C. J., Gaw, A., et al. (1993). Fenofibrate and metabolic heterogeneity in hypercholesterolaemia. Arterioscleros. Thromb., 13, 702-709.
24. Gaw, A., Packard, C. J., Caslake, M. J., et al. (1994). Effects of ciprofibrate on LDL metabolism in man. Atherosclerosis, 108, 137-48.
25. Superko, H. R., Krauss, R. M., DiRicco, R. N. (1997). Effect of fluvastatin on low-density lipoprotein peak particle diameter. Am. J. Cardiol., 80, 78-81.
26. Cheung, M. C., Austin, M. A., Moulin, P. et al. (1993). Effects of pravastatin on apolipoprotein-specific high density lipoprotein subpopulations and low density lipoprotein subclass phenotypes in patients with primary hypercholesterolaemia. Atherosclerosis, 102, 107-119.
27. Jokubaitis, L. A. (1996). Development and pharmacology of fluvastatin. Br. J. Clin. Pract. Symp. (Suppl), 77A, 11-15.
28. Jokubaitis, L. A. (1994). Updated clinical safety experience with fluvastatin. Am. J. Cardiol., 73(14), 18D-24D.
29. Li, P. K., Mak, T. W., Wang, A. Y. et al. (1995). The interaction of fluvastatin and cyclosporin A in renal transplant patients. Int. J. Clin. Pharmacol. Ther., 33(4), 246-248.
30. Farnier, M. and Leneveur-Ledoux, L. (1996). French Fluvastatin Study Group. Comparison of fenofibrate monotherapy and two combined fluvastatin/fenofibrate therapy in primary hypercholesterolaemia (abstract). 66th European Atherosclerosis Society Meeting, July 13, Florence, 210.